CDXG: In the first half of 2025, revenue from controllable nuclear fusion-related products will account for less than 1% of the company's main business revenue
I'm PortAI, I can summarize articles.
CDXG announced that the revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025. The company's stock experienced an abnormal fluctuation, with the cumulative closing price deviation reaching 20% over three consecutive trading days from October 9 to October 13, 2025. After verification, the board of directors and major shareholders confirmed that there are no undisclosed significant matters. The electronic tubes independently developed by the company are used in controllable nuclear fusion RF power devices
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments